T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer.
Cristina Suarez Rodriguez,James Larkin,Poulam M. Patel,Begoña P. Valderrama,Alejo Rodriguez-Vida,Hilary Glen,Fiona C Thistlethwaite,Christy Ralph,Gopalakrishnan Srinivasan,María José Méndez Vidal,Abigail Carter,Charlotte Tyson,Aaron Prendergast,Kelly Mousa,Thomas Powles +14 more
TL;DR: There is a strong rationale for investigating MET and PD-L1 inhibition in metastatic papillary renal cancer (PRC), and a previously reported response rates (RR) and progression free progression-free survival rates ( RR) are encouraging.
Journal ArticleDOI
Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer.
Grant D. Stewart,Thomas Powles,Thomas Powles,Christophe Van Neste,Alison M. Meynert,Fiach C. O'Mahony,Alexander Laird,Dieter Deforce,Filip Van Nieuwerburgh,Geert Trooskens,Wim Van Criekinge,Tim De Meyer,David J. Harrison +12 more
TL;DR: Demonstration of relative methylome homogeneity and consistent VHL hypermethylation, after sunitinib, may overcome the hurdle of ITH present at other molecular levels for biomarker research.
Journal ArticleDOI
First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Keiichiro Mori,Benjamin Pradere,Marco Moschini,Hadi Mostafaei,Ekaterina Laukhtina,Victor M. Schuettfort,Reza Sari Motlagh,Francesco Soria,Jeremy Yuen-Chun Teoh,Shin Egawa,Thomas Powles,Shahrokh F. Shariat +11 more
TL;DR: In this paper, the role of ICIs alone or in combination as first-line treatment in chemotherapy-eligible patients with metastatic urothelial carcinoma (mUC) was assessed.
Journal ArticleDOI
Salvage high-dose chemotherapy for germ cell tumors
TL;DR: Salvage HDCT with ASCT can cure a significant proportion of patients with GCT and progression after one or more lines of cisplatin-based chemotherapy and thus plays an important role in the contemporary management of high-risk patients.
Journal ArticleDOI
A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).
Thomas Powles,Joshua J. Meeks,Matthew D. Galsky,Michiel S. van der Heijden,Hiroyuki Nishiyama,Hikmat Al-Ahmadie,Erik T. Goluboff,Stephan Hois,Sarah E. Donegan,Vanessa Williams,Feng Xiao,James W.F. Catto +11 more
TL;DR: Durvalumab (anti–PD-L1 antibody) combined with gemcitabine + cisplatin, administered as either neoadjuvant or adjuvant treatment, may increase the rate of pathologic response and prolong long-term survival in patients with muscle-invasive bladder cancer.